Page 160 - Drug Class Review
P. 160
Page 110 of 205
Drug Effectiveness Review Project
placebo 78.9% 13.1% 7.5% 11.3% 9.9% 5.6% 4.7% 4.2% placebo 19.2% 7.5%
galantamine 32 mg/d 92.4% 43.6% 25.6% 18.5% 19.4% 20.4% 10.9% 10.9% galantamine 32 mg/d 42.2% 31.8%
Yes
galantamine 24 mg/d 92.0% 37.3% 20.8% 13.7% 12.3% 13.7% 12.3% 6.6% ation exclusions: NR Overall loss to follow-up: 31.1% Loss to follow-up differential high: galantamine 24 mg/d 32.1% 23.1%
NR ITT: Yes Post randomiz Yes Yes Yes Fair
rse events:
Final Report Update 1 Authors: Raskind et al. Year: 2000 ADVERSE EVENTS: Overall adverse effects reported: Nausea • Vomiting • Dizziness • Diarrhea • Anorexia • Weight loss • Abdominal pain • Significant differences in adverse events: ANALYSIS: ADEQUATE RANDOMIZATION: ADEQUATE ALLOCATION CONCEALMENT: BLINDING OF OUTCOME ASSESSORS: ATTRITION (overall): ATTRITION (treatment specific): Loss to follow-up: Withdrawals due to adve QUALITY RATING: *primary outcome measures Alzheimer's Drugs
